An analysis of Medicare accountable care organizations (ACOs) revealed that those with more primary care physicians performed better on preventive care quality measures and infrastructure and financing were also predictive of better performance, explained Mariétou Ouayogodé, PhD, post-doctoral fellow at The Dartmouth Institute for Health Policy and Clinical Practice at the Geisel School of Medicine at Dartmouth.
An analysis of Medicare accountable care organizations (ACOs) revealed that those with more primary care physicians performed better on preventive care quality measures and infrastructure and financing were also predictive of better performance, explained Mariétou Ouayogodé, PhD, post-doctoral fellow at The Dartmouth Institute for Health Policy and Clinical Practice at the Geisel School of Medicine at Dartmouth.
Transcript
What have you learned about the quality of care in Medicare accountable care organizations?
What we've learned from our analysis was mainly that preventive care quality measures are very much correlated and so when we used our data reduction tool, which was the exploratory factor analysis, we could segment them into 2 main subgroups. So we had some measures describing disease prevention and then on the other side we had wellness screening measures.
When we took it to more analysis to examine associations with ACO characteristics we came to that analysis with expectations that probably the size of an ACO as measured with beneficarcy composition or even physician composition could be predictive of performance on preventive care quality.
But when we looked at size as measured with the number of attributed beneficiaries, we don't see that significant prediction being there. But when we control for that we found that ACOs performed significantly worse when they had fewer primary care providers and too many specialists. So that's what we've learned, and we've also learned that some characteristics with ACOs related to infrastructure and financing were actually predictive of better performance on disease prevention—so preventive care quality, in general.
The Latest in New and Emerging Therapies in Schizophrenia: Dr Megan Ehret
October 22nd 2024In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.
Read More
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
Bimekizumab Poised to Tackle Unmet HS Treatment Needs
October 18th 2024Hidradenitis suppurativa (HS) is an inflammatory, chronic disease with very high symptom and physical burdens, and it can get progressively worse over time if it's inadequately treated, explained Amit Garg, MD, founding chair, Department of Dermatology, Northwell Health.
Read More
Expanding Access to NSCLC Innovations: Challenges and Opportunities
October 18th 2024The current research focus for Umit Tapan, MD, Boston Medical Center, is reducing disparities in lung cancer care and improving treatment access, in particular for immunotherapy and targeted treatments.
Read More